Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926052 · ClinicalTrials.gov registry record · Phase 3
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
A Phase 3 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
NCT03926052 is a Phase 3 study that has completed, run by Yale University. The registered enrollment target is 61 participants.
The verdict
NCT03926052, a Phase 3 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
Study Summary
This study will test the effectiveness of lisdexamfetamine (LDX) medication as a maintenance therapy for the treatment of binge-eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst responders to acute treatments, LDX medication results in superior maintenance and longer-term outcomes compared with placebo.
Interventions
- DRUG Placebo
- DRUG Lisdexamfetamine Dimesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2024-11-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03926052
The ClinicalTrials.gov registry entry for NCT03926052 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03926052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03926052 about?
NCT03926052 is a clinical study titled "Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment". This study will test the effectiveness of lisdexamfetamine (LDX) medication as a maintenance therapy for the treatment of binge-eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst responders to acute treatments, LDX medication results in superior maintenance...
What is the current status of trial NCT03926052?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2019-08-07. Estimated completion is 2024-11-18.
What interventions are being tested in trial NCT03926052?
The interventions under investigation include: Placebo (DRUG), Lisdexamfetamine Dimesylate (DRUG).
Who is sponsoring clinical trial NCT03926052?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.